Lipoproteins

Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease

Retrieved on: 
Monday, September 6, 2021
Research, Fitness & Nutrition, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Lipids, Medical specialties, Branches of biology, Sterols, Cardiology, Lipoproteins, Lipid metabolism disorders, Low-density lipoprotein, Hypercholesterolemia, Cholesterol, Lipid-lowering agent, Phytosterol

In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.

Key Points: 
  • In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.
  • The HEART clinical study is a multicenter, international, randomized, placebo-controlled, double-blind study involving 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL.
  • The primary endpoint of the HEART study is the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease and in particular atherosclerosis, and it has several secondary objectives of interest.
  • The medical need is real: according to the WHO, nearly 40% of the world's adult population has high cholesterol, a well-known cardiovascular risk factor.

Oakland University-led research shows resistance training can help reduce type 2 diabetes risk

Retrieved on: 
Wednesday, June 16, 2021
Diabetes, Molecules, Branches of biology, Cardiology, Lipoproteins, Clinical medicine, Low-density lipoprotein, Type 2 diabetes, Fat, BaleDoneen Method, Diabetes management

ROCHESTER, Mich., June 16, 2021 /PRNewswire/ -- A group of Oakland University researchers used data from medical studies around the world to examine the impact of resistance training on type 2 diabetes risk.

Key Points: 
  • ROCHESTER, Mich., June 16, 2021 /PRNewswire/ -- A group of Oakland University researchers used data from medical studies around the world to examine the impact of resistance training on type 2 diabetes risk.
  • Their findings, published in the journal Sports Medicine , showed that resistance training like weight lifting and resistance band exercise is helpful for controlling blood sugar and blood lipid ( LDL, HDL and Triglycerides ) levels two of the most prominent risk factors for type 2 diabetes.
  • "Our research showed that resistance training is also useful for controlling those same variables, in addition to reducing body fat, in people who are at risk for developing the disease."
  • The researchers pulled data from controlled clinical trials that tracked cardiometabolic outcomes in adults with type 2 diabetes risk, comparing those who underwent a resistance training intervention with those who did not.

COVID-19 Increases Rate of Heart Attacks in People with Genetic High Cholesterol and Heart Disease

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Circulatory system, Cardiovascular system, Lipid metabolism disorders, Cardiology, Lipoproteins, Cardiovascular diseases, Familial hypercholesterolemia, Hypercholesterolemia, Cholesterol, Low-density lipoprotein, Coronary artery disease

PASADENA, Calif., May 27, 2021 /PRNewswire/ --Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation .

Key Points: 
  • PASADENA, Calif., May 27, 2021 /PRNewswire/ --Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation .
  • Published online in the American Journal of Preventive Cardiology, the study also importantly confirms that COVID-19 increases heart attack rates in individuals with established atherosclerotic cardiovascular disease (ASCVD).
  • The researchers found that rates of heart attacks were highest in those with a COVID-19 diagnosis and the presence of diagnosed FH or probable FH with known ASCVD.
  • Familial hypercholesterolemia is a common genetic condition that increases an individual's risk for cardiovascular disease by up to 20-fold due to lifelong elevated low density lipoprotein cholesterol (LDL-C) levels.

Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21

Retrieved on: 
Saturday, May 15, 2021
Medical specialties, Circulatory system, Cardiovascular system, Cardiology, Lipoproteins, Bempedoic acid, Statin, Low-density lipoprotein, Cardiovascular disease, Lipid-lowering agent

Using observed changes in LDL-C at week 12, researchers applied the CTT coefficient to calculate an estimated 10-year cardiovascular event relative risk reduction rate.

Key Points: 
  • Using observed changes in LDL-C at week 12, researchers applied the CTT coefficient to calculate an estimated 10-year cardiovascular event relative risk reduction rate.
  • In these studies, NEXLETOL provided an average of 18% placebo-corrected LDL-C lowering at week 12 when used with moderate or high-intensity statins.
  • The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.\nElevations in serum uric acid have occurred.
  • \xe2\x80\x9cRationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.\xe2\x80\x9d American Heart Journal.

Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Cardiology, Lipids, PCSK9, Branches of biology, Cardiology, Lipoproteins, Low-density lipoprotein receptor gene family, Low-density lipoprotein, LDL receptor, Cholesterol, P-21, Shifa Biomedical Corporation, Xontogeny, LLC, P-21, SHIFA BIOMEDICAL CORPORATION, XONTOGENY, LLC

Shifa\xe2\x80\x99s lead molecule, P-21, acts as a PCSK9/LDLR-antagonist to modulate the degradation of the LDLR in the liver, thereby regulating cholesterol homeostasis.

Key Points: 
  • Shifa\xe2\x80\x99s lead molecule, P-21, acts as a PCSK9/LDLR-antagonist to modulate the degradation of the LDLR in the liver, thereby regulating cholesterol homeostasis.
  • \xe2\x80\x9cThis seed investment will enable us to rapidly advance our drug product with efficient capital deployment and execute a successful development program.
  • Intervention with drugs to reduce LDL-C has proven to decrease the risk of subsequent cardiovascular events, including mortality.
  • It is a privately held biopharmaceutical company dedicated to the cost-effective development of drugs for the treatment of cardiovascular disease.

Eating a Nic's Keto Healthy Fatty Diet Reduce Body Weight and Improve Cardiovascular Health Markers!

Retrieved on: 
Wednesday, May 5, 2021
Lipids, Branches of biology, Cardiology, Lipoproteins, Medical specialties, Diets, Nutrition, Low-density lipoprotein, High-density lipoprotein, Cholesterol, Therapeutic Lifestyle Changes, BaleDoneen Method

b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

Key Points: 
  • b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

Eating a Nic's Keto Healthy Fatty Diet Reduce Body Weight and Improve Cardiovascular Health Markers!

Retrieved on: 
Wednesday, May 5, 2021
Lipids, Branches of biology, Cardiology, Lipoproteins, Medical specialties, Diets, Nutrition, Low-density lipoprotein, High-density lipoprotein, Cholesterol, Therapeutic Lifestyle Changes, BaleDoneen Method

b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

Key Points: 
  • b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

2021 World Immunodiagnostics Market Assessment of 97 Countries - Featuring Agilent Technologies, bioMerieux and Eiken Chemical Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, April 23, 2021
Medical devices, Health, Branches of biology, Medical specialties, Clinical medicine, GABAA receptor positive allosteric modulators, Cardiology, Lipoproteins, Blood tests, High-density lipoprotein, Ferritin, Cholesterol, Niacin, Bilirubin

b'This new 97-country report is available by region, country, market segment, section, or individual test.\nThe report is available by section, and can be customized to specific information needs and budget.\nThe report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both centralized (hospitals, commercial laboratories), and POC/decentralized locations.

Key Points: 
  • b'This new 97-country report is available by region, country, market segment, section, or individual test.\nThe report is available by section, and can be customized to specific information needs and budget.\nThe report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both centralized (hospitals, commercial laboratories), and POC/decentralized locations.
  • The report explores future market trends; forecasts specimen, test and sales volume; estimates sales and market shares of key suppliers in major countries; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities for reagent and instrument suppliers.\nClinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.
  • Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.
  • This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.\nEstimates of facilities performing clinical chemistry and immunodiagnostic tests in major countries.\nTest volume and sales projections.\nComprehensive review of the market dynamics, trends, structure, size, growth, and key suppliers.\nTest volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays.\nAlbumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin (Direct), Bilirubin (Total), BNP, BUN (Blood Urea Nitrogen), Calcium, Carbon Dioxide/Bicarbonate, Cardio CRP, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Cystatin C, Ferritin, Fructosamine, GGT, Glucose, HDL Cholesterol, Homocysteine, hs-CRP, Insulin, Iron, Iron (Total Binding Capacity), Iron (Unsaturated Binding Capacity), LDH, LDL Cholesterol, LDL Cholesterol Direct, Lipase, Lipoprotein a, Magnesium, Microalbumin, NT-proBNP, Phosphorus, Potassium, Sodium, ST2, Total Protein, Triglycerides, Troponin, Uric Acid\nAFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid), Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood, PAP, PSA, Thyroglobulin, Vitamin B-12\nAnalysis of current and emerging clinical chemistry and immunodiagnostic tests.\nReview of current instrumentation technologies, and feature comparison of high-, medium-, and low-volume/POC analyzers.\nAssessment of current and emerging technologies, and their potential market applications.\nCompanies developing or marketing new technologies and products by test.\nNew product development opportunities with significant market appeal.\nPotential market entry barriers and risks.\nStrategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.\nThe companies analyzed in the report include:\n'

Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 6, 2021
Finance, Money, Economy, Corporate finance, Stock market, Cardiology, Lipoproteins, Low-density lipoprotein, Investment, Twitter, Webcast, REPLAY

A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/ .

Key Points: 

Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test

Retrieved on: 
Wednesday, March 17, 2021
Lipids, Branches of biology, Cardiology, Lipoproteins, Molecules, Ceramide, Low-density lipoprotein, Cholesterol

Quest plans to develop a test service based on Zora's ceramide technology as an aid in identifying patients at risk for cardiovascular-related disease and death, assuming successful test development and favorable market conditions.

Key Points: 
  • Quest plans to develop a test service based on Zora's ceramide technology as an aid in identifying patients at risk for cardiovascular-related disease and death, assuming successful test development and favorable market conditions.
  • Zora's ceramide-based technology can take cardiovascular testing beyond LDL cholesterol to the next level of precision in cardiovascular diagnostics.
  • Zora Biosciences Oy employs its ceramide-based technology in a test service called CERT available in Finland with plansto expand availability across Europe near term.
  • Zora's flagship test is the ceramide based, CERT, Cardiovascular Event Risk Test.